Generic Version of Copaxone Available

The first generic multiple sclerosis disease modifying therapy (DMT) was released onto the market on June 18, after a federal appeals court invalidated a patent for Teva’s widely used brand-name therapy Copaxone. Glatopa, the generic drug made by Sandoz and Momenta Pharmaceuticals, was approved by the Food and Drug Administration (FDA) back in April 2015 as a once per day treatment for relapsing types of multiple sclerosis.

Multiple sclerosis patients are hoping the release of a generic DMT will come with a smaller price tag than previous therapies on the market. As of release, Novartis, who owns Sandoz, said Glatopa will have a wholesale price of $63,000 per a year, which will make it 18% less expensive than Copaxone. The cost for the generic could reduce further, if insurers agree to offer discounts and rebates for the treatment.1,2

Currently, Copaxone accounts for approximately 30% of prescriptions, the largest for multiple sclerosis treatments. Prior to invalidation, the Copaxone patent was to end in September 2015.3,4

View References


View Comments (3)